Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Detalles Bibliográficos
Autores principales: Chantkran, Wittawat, Hsieh, Ya-Ching, Zheleva, Daniella, Frame, Sheelagh, Wheadon, Helen, Copland, Mhairi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260774/
https://www.ncbi.nlm.nih.gov/pubmed/34230455
http://dx.doi.org/10.1038/s41420-021-00558-1
_version_ 1783718877702651904
author Chantkran, Wittawat
Hsieh, Ya-Ching
Zheleva, Daniella
Frame, Sheelagh
Wheadon, Helen
Copland, Mhairi
author_facet Chantkran, Wittawat
Hsieh, Ya-Ching
Zheleva, Daniella
Frame, Sheelagh
Wheadon, Helen
Copland, Mhairi
author_sort Chantkran, Wittawat
collection PubMed
description
format Online
Article
Text
id pubmed-8260774
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82607742021-07-23 Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML Chantkran, Wittawat Hsieh, Ya-Ching Zheleva, Daniella Frame, Sheelagh Wheadon, Helen Copland, Mhairi Cell Death Discov Correction Nature Publishing Group UK 2021-07-06 /pmc/articles/PMC8260774/ /pubmed/34230455 http://dx.doi.org/10.1038/s41420-021-00558-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correction
Chantkran, Wittawat
Hsieh, Ya-Ching
Zheleva, Daniella
Frame, Sheelagh
Wheadon, Helen
Copland, Mhairi
Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
title Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
title_full Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
title_fullStr Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
title_full_unstemmed Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
title_short Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
title_sort correction to: interrogation of novel cdk2/9 inhibitor fadraciclib (cyc065) as a potential therapeutic approach for aml
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260774/
https://www.ncbi.nlm.nih.gov/pubmed/34230455
http://dx.doi.org/10.1038/s41420-021-00558-1
work_keys_str_mv AT chantkranwittawat correctiontointerrogationofnovelcdk29inhibitorfadraciclibcyc065asapotentialtherapeuticapproachforaml
AT hsiehyaching correctiontointerrogationofnovelcdk29inhibitorfadraciclibcyc065asapotentialtherapeuticapproachforaml
AT zhelevadaniella correctiontointerrogationofnovelcdk29inhibitorfadraciclibcyc065asapotentialtherapeuticapproachforaml
AT framesheelagh correctiontointerrogationofnovelcdk29inhibitorfadraciclibcyc065asapotentialtherapeuticapproachforaml
AT wheadonhelen correctiontointerrogationofnovelcdk29inhibitorfadraciclibcyc065asapotentialtherapeuticapproachforaml
AT coplandmhairi correctiontointerrogationofnovelcdk29inhibitorfadraciclibcyc065asapotentialtherapeuticapproachforaml

Ejemplares similares